Log inSign up
AAOIFI No. 21 screening

Is RNA halal?

Atrium Therapeutics, Inc.

Not halal

Atrium Therapeutics, Inc. did not pass AAOIFI screening. The failed check is shown below.

Checked: 16 October 2026

Exchange

NASDAQ

Price

7.67

Day

-1.92%

Market cap

$133.1M

Industry

Biotechnology

Sector

Healthcare

What the company does

Atrium Therapeutics (San Diego) develops RNA drugs (siRNA) delivered to the heart for genetic cardiomyopathies, at preclinical/early clinical stage; it was carved out of Avidity Biosciences' cardiac programs. No commercial product; funded by investors and collaborations.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ current market cap $133.08M = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $263.90M ÷ current market cap $133.08M = 198.3%

    198.3%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.